Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis. - Wikidata - awgldk - TriplyDB

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

http://www.wikidata.org/entity/Q33406478

about

Gambogic acid regulates the migration and invasion of colorectal cancer via microRNA-21-mediated activation of phosphatase and tensin homolog

P2860

Q57163660-500977E6-590D-470E-98FA-432EB95377BE

P2860

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

http://www.wikidata.org/entity/Q33406478

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@ast

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@en

type

label

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@ast

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@en

prefLabel

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@ast

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@en

P1433

Q33406478-7CE22EDB-6239-4CBF-A175-A83D9EE061B8

P1476

Q33406478-BE682552-9BF4-403A-8BD2-1EB3AFE23B6B

P2093

Q33406478-7735171C-093C-4D97-8699-5702882BB5B1

P2860

Q33406478-05A32E15-F6D0-4F0A-8CF1-1135676B7E8A

Q33406478-0A179F74-7026-4A76-A93E-1F83AA527FBC

Q33406478-0BADA2B1-42C2-4DC8-AEC1-6540FF8A890A

Q33406478-0EFCCDD8-074C-4B1D-95E9-C2DB5B699374

Q33406478-107FE1AB-B081-4F72-9B00-36B48F5CE6F7

Q33406478-14E3E2EF-57D1-47A9-BBFC-16A80DB211C3

Q33406478-1620CA08-B418-4DB0-9583-304EAD18CD49

Q33406478-1EB52CBF-7A5A-4B8E-A93D-92A3686BAC19

Q33406478-375C9D2C-9E2A-49DE-8227-AAD3B854C822

Q33406478-39AFBC61-7C9C-4952-AA23-5BF32AC19017

P2888

Q33406478-6F835C5D-26B9-4682-AF03-B1BAC60227BF

P304

Q33406478-75B800C1-260F-409C-B142-E46FFD59CF06

P31

Q33406478-FEC0748B-DB14-414B-A3D0-7828A70E9EB3

P356

Q33406478-11ECC00C-7841-4E58-9679-A4590719069D

P433

Q33406478-0F418E1A-9D11-4545-BDA8-62DFBCBA8258

P478

Q33406478-02299188-5E18-4CCC-9B71-BB4DE12236EC

P577

Q33406478-5A91D6A5-CC90-427F-806D-2FC7D34F225E

P6179

Q33406478-C7C86684-D71E-4472-9D74-24651959A7B1

P698

Q33406478-6618781A-EFD9-42E8-894D-0ED8AC29563C

P921

Q33406478-40DF9845-EB5E-4DAA-8ECE-D0185889F650

P356

S11864-013-0229-5

P1433

Current Treatment Options in Oncology

P1476

Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

@en

P2093

Sanford Kempin

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

P2888

s11864-013-0229-5

P304

144-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-013-0229-5

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005818281

http://www.w3.org/2001/XMLSchema#string

P698

23494726

http://www.w3.org/2001/XMLSchema#string

P921